دورية أكاديمية
أعرض في EDS

Population Pharmacokinetic and Pharmacodynamic Analysis of Dalbavancin for Long-Term Treatment of Subacute and/or Chronic Infectious Diseases: The Major Role of Therapeutic Drug Monitoring.

التفاصيل البيبلوغرافية
العنوان: Population Pharmacokinetic and Pharmacodynamic Analysis of Dalbavancin for Long-Term Treatment of Subacute and/or Chronic Infectious Diseases: The Major Role of Therapeutic Drug Monitoring.
المؤلفون: Cojutti PG; Clinical Pharmacology Unit, Department for Integrated Infectious Risk Management, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy., Tedeschi S; Infectious Diseases Unit, Department for Integrated Infectious Risk Management, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.; Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, 40138 Bologna, Italy., Gatti M; Clinical Pharmacology Unit, Department for Integrated Infectious Risk Management, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.; Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, 40138 Bologna, Italy., Zamparini E; Infectious Diseases Unit, Department for Integrated Infectious Risk Management, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy., Meschiari M; Department of Infectious Diseases and Tropical Medicine, Azienda Ospedaliero-Universitaria di Modena, 41124 Modena, Italy., Siega PD; Infectious Diseases Clinic, Santa Maria della Misericordia University Hospital of Udine, ASUFC, 33100 Udine, Italy., Mazzitelli M; Infectious and Tropical Diseases Unit, Padua University Hospital, 35128 Padua, Italy., Soavi L; UOC Malattie Infettive, ASST Papa Giovanni XXIII, 24127 Bergamo, Italy., Binazzi R; UOC Malattie Infettive, Azienda Sanitaria dell'Alto Adige, 39100 Bolzano, Italy., Erne EM; UOC Malattie Infettive, Azienda Sanitaria dell'Alto Adige, 39100 Bolzano, Italy., Rizzi M; UOC Malattie Infettive, ASST Papa Giovanni XXIII, 24127 Bergamo, Italy., Cattelan AM; Infectious and Tropical Diseases Unit, Padua University Hospital, 35128 Padua, Italy., Tascini C; Infectious Diseases Clinic, Santa Maria della Misericordia University Hospital of Udine, ASUFC, 33100 Udine, Italy., Mussini C; Department of Infectious Diseases and Tropical Medicine, Azienda Ospedaliero-Universitaria di Modena, 41124 Modena, Italy., Viale P; Infectious Diseases Unit, Department for Integrated Infectious Risk Management, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.; Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, 40138 Bologna, Italy., Pea F; Clinical Pharmacology Unit, Department for Integrated Infectious Risk Management, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.; Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, 40138 Bologna, Italy.
المصدر: Antibiotics (Basel, Switzerland) [Antibiotics (Basel)] 2022 Jul 24; Vol. 11 (8). Date of Electronic Publication: 2022 Jul 24.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101637404 Publication Model: Electronic Cited Medium: Print ISSN: 2079-6382 (Print) Linking ISSN: 20796382 NLM ISO Abbreviation: Antibiotics (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI AG, 2012-
مستخلص: A population pharmacokinetic analysis of dalbavancin was conducted in patients with different infection sites. Non-linear mixed effect modeling was used for pharmacokinetic analysis and covariate evaluation. Monte Carlo simulations assessed the probability of target attainment (PTA) of total dalbavancin concentration ≥ 8.04 mg/L over time (associated with ≥90% probability of optimal pharmacodynamic target attainment of fAUC24h/MIC > 111.1 against S. aureus) associated with a single or double dosage, one week apart, of 1000 or 1500 mg in patients with different classes of renal function. Sixty-nine patients with 289 concentrations were included. Most of them (53/69, 76.8%) had bone and joint infections. A two-compartment model adequately fitted dalbavancin concentration−time data. Creatinine clearance (CLCR) was the only covariate associated with dalbavancin clearance. Monte Carlo simulations showed that, in patients with severe renal dysfunction, the 1000 mg single or double one week apart dosage may ensure optimal PTAs of 2 and 5 weeks, respectively. In patients with preserved renal function, the 1500 mg single or double one-week apart dosage may ensure optimal PTAs of 2 and 4 to 6 weeks, respectively. Therapeutic drug monitoring should be considered mandatory for managing inter-individual variability and for supporting clinicians in long-term treatments of subacute and chronic infections.
References: J Glob Antimicrob Resist. 2019 Sep;18:195-198. (PMID: 30926464)
Clin Microbiol Rev. 2015 Jul;28(3):603-61. (PMID: 26016486)
Front Microbiol. 2021 Oct 22;12:749685. (PMID: 34745053)
Clin Pharmacokinet. 2022 Mar;61(3):363-374. (PMID: 34931283)
J Clin Pharmacol. 2009 Apr;49(4):465-76. (PMID: 19318696)
Antimicrob Agents Chemother. 2019 Apr 25;63(5):. (PMID: 30858217)
Antimicrob Agents Chemother. 2021 Mar 1;:. (PMID: 33649108)
Molecules. 2020 Jun 23;25(12):. (PMID: 32586045)
Clin Infect Dis. 2005 Feb 1;40(3):374-80. (PMID: 15668859)
Antimicrob Agents Chemother. 2015 Dec;59(12):7833-6. (PMID: 26392492)
Antimicrob Agents Chemother. 2004 Mar;48(3):940-5. (PMID: 14982787)
Clin Infect Dis. 2018 Aug 16;67(5):795-798. (PMID: 29659732)
Diagn Microbiol Infect Dis. 2019 Mar;93(3):213-218. (PMID: 30396697)
Emerg Microbes Infect. 2018 Dec 5;7(1):202. (PMID: 30514923)
J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Sep 1;879(25):2632-41. (PMID: 21831727)
Int J Antimicrob Agents. 2021 Nov;58(5):106445. (PMID: 34614441)
Ann Clin Microbiol Antimicrob. 2019 Oct 19;18(1):30. (PMID: 31629409)
Ann Intern Med. 2009 May 5;150(9):604-12. (PMID: 19414839)
Clin Pharmacol Drug Dev. 2020 Jan;9(1):21-31. (PMID: 31087630)
J Glob Antimicrob Resist. 2016 Dec;7:178-186. (PMID: 27889013)
Antimicrob Agents Chemother. 2015 Apr;59(4):1849-55. (PMID: 25561338)
Infect Dis Ther. 2015 Sep;4(3):245-58. (PMID: 26341488)
Drug Des Devel Ther. 2021 Aug 03;15:3349-3378. (PMID: 34376971)
J Clin Pharmacol. 2005 Nov;45(11):1279-87. (PMID: 16239361)
فهرسة مساهمة: Keywords: dalbavancin; long-term treatment; off-label use; population pharmacokinetics; therapeutic drug monitoring
تواريخ الأحداث: Date Created: 20220727 Latest Revision: 20230308
رمز التحديث: 20230309
مُعرف محوري في PubMed: PMC9331863
DOI: 10.3390/antibiotics11080996
PMID: 35892386
قاعدة البيانات: MEDLINE
الوصف
تدمد:2079-6382
DOI:10.3390/antibiotics11080996